ClinicalTrials.Veeva

Menu

Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis

M

Medical University of Graz

Status

Enrolling

Conditions

Multiple Sclerosis

Treatments

Other: blood sample

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained

Full description

The current study aims to comprehensively investigate the individual clinical, morphological and biochemical aspects of MS in order to elucidate underlying mechanisms leading to disease progression. This shall ultimately serve to identify imaging and biochemical markers, which may support clinical management of persons with MS (pwMS). The following markers will be assessed: demographics (age, sex), clinical (EDSS at baseline, disease duration); neuropsychological (SDMT (Symbol Digit Modalities Test) score); MRI (Magnetic Resonance Imaging) (lesion load, atrophy); Biochemical markers analyzed in cerebrospinal fluid (CSF), blood, DNA, RNA, peripheral blood mononuclear cells (PBMCs)

Enrollment

500 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with suspected or proven multiple sclerosis
  • The participants are patients who are in inpatient or outpatient care of the Department of Neurology at the Medical University of Graz, Austria

Exclusion criteria

  • Excluded from the examinations are all patients for whom an MRI examination is impossible or problematic

Trial contacts and locations

1

Loading...

Central trial contact

Christian Enzinger, Prof.; Michael Khalil, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems